Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

3.160 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 56
Open 3.160
Bid (Size) 3.160 (2)
Ask (Size) 3.340 (1)
Prev. Close 3.160
Today's Range 3.160 - 3.160
52wk Range 0.8500 - 6.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Appoints Michael Shankman as Chief Financial Officer
Via ACCESSWIRE

Performance

YTD
+144.96%
+144.96%
1 Month
-13.42%
-13.42%
3 Month
+20.61%
+20.61%
6 Month
-8.93%
-8.93%
1 Year
+227.46%
+227.46%

More News

Read More
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Via ACCESSWIRE
Lexaria Welcomes Industry Veteran as New CEO
Via ACCESSWIRE
First Results from Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study
Via Investor Brand Network
Lexaria Releases Strategic Letter from the Outgoing CEO
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Additional Tolerability, PK Test Results
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.